Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Behavioural phenotyping assays for mouse models of autism
Silverman, J. L., Yang, M., Lord, C., & Crawley, J. N. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2851 · Cited by 1,462
Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
“Tsc2+/ mice however exhibit normal social preference in a three-chamber test (Ehninger et al., 2008; Ehninger et al., 2012) but deficient social interaction in a dyadic reciprocal social test (Sato et al., 2012).”
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Peñagarikano, O., Abrahams, B. S., Herman, E. I., Winden, K. D., Gdalyahu, A., Dong, H., Sonnenblick, L. I., Gruver, R., Almajano, J., Bragin, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.040 · Cited by 1,075
“Recent studies in mouse models are very encouraging in this regard, including Rett syndrome (Guy et al., 2007), fragile X syndrome (Dölen et al., 2007), neurofibromatosis type 1 (Costa et al., 2002), Down’s syndrome (Fernandez et al., 2007), and tuberous sclerosis (Ehninger et al., 2008).”
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders
Nelson, S. B., & Valakh, V. (2015) · Neuron · doi:10.1016/j.neuron.2015.07.033 · Cited by 1,001
Translational control of long-lasting synaptic plasticity and memory
Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009) · Neuron · doi:10.1016/j.neuron.2008.10.055 · Cited by 944
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Advancing the understanding of autism disease mechanisms through genetics
de la Torre-Ubieta, L., Won, H., Stein, J. L., & Geschwind, D. H. (2016) · Nature Medicine · doi:10.1038/nm.4071 · Cited by 827
“Translational inhibition by eukaryotic translation initiation factor (eIF) 4E and eIF4G interaction inhibitor (4EGI-1) and rapamycin have been effective in alleviating behavioral and neuronal phenotypes in models with perturbations in the mTOR pathway 144,183–186 , 240– 242 .”
Zoghbi, H. Y., & Bear, M. F. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009886 · Cited by 797
“One particularly interesting phenotype reported in the Tsc2 +/ − mouse is an enhancement of late-phase LTP (Ehninger et al. 2008a).”
BackgroundInfluentialPostsynaptic BDNF‐TrkB signaling in synapse maturation, plasticity, and disease
Yoshii, A., & Constantine‐Paton, M. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20765 · Cited by 744
Lipton, J. O., & Sahin, M. (2014) · Neuron · doi:10.1016/j.neuron.2014.09.034 · Cited by 736
“which are reversible by a short course of rapamycin administration even in adulthood (Ehninger et al., 2008).”
InfluentialActivity-dependent neuronal signalling and autism spectrum disorder
Ebert, D. H., & Greenberg, M. E. (2013) · Nature · doi:10.1038/nature11860 · Cited by 666
Disentangling the heterogeneity of autism spectrum disorder through genetic findings
Jeste, S. S., & Geschwind, D. H. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.278 · Cited by 644
“30,31 Moreover, mice with heterozygous and homozygous loss of TSC1 localized to the cerebellum show abnormal social interaction, as well as repetitive behaviours and vocalizations.”
Bourgeron, T. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.06.003 · Cited by 637
Neurodevelopmental Disorders: From Genetics to Functional Pathways
Parenti, I., Rabaneda, L. G., Schoen, H., & Novarino, G. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.05.004 · Cited by 618
Neurological and neuropsychiatric aspects of tuberous sclerosis complex
Curatolo, P., Moavero, R., & de Vries, P. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00069-1 · Cited by 600
The Autistic Neuron: Troubled Translation?
Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598
“Taken together, the association of mutations in FMRP, TSC1/2, and PTEN with autism suggests that defects in translational repression may represent one possible mechanism leading to autistic phenotypes.”
BackgroundInfluentialMutations causing syndromic autism define an axis of synaptic pathophysiology
Auerbach, B. D., Osterweil, E. K., & Bear, M. F. (2011) · Nature · doi:10.1038/nature10658 · Cited by 592
“Like FXS, (1) TSC is a singlegene disorder with core symptoms of ASD and ID, (2) the affected gene(s) lie in a signaling pathway that couples cell surface receptors to mRNA translation, (3) there are well validated mouse models of the disease, and (4) some mutant phenotypes in these mouse models have responded to phar…”
BackgroundFighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez-Vicente, M., & Vila, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3068 · Cited by 525
Autism-related deficits via dysregulated eIF4E-dependent translational control
Gkogkas, C. G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T., Weatherill, D. B., Vasuta, C., Yee, S., Truitt, M., Dallaire, P., et al. (2013) · Nature · doi:10.1038/nature11628 · Cited by 522
Geschwind, D. H. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.053107.121225 · Cited by 512
Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders
Lee, E., Lee, J., & Kim, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.011 · Cited by 468
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441
“More importantly, a recent study suggested that Tsc2 / mice show deficits in learning and memory that could be reversed by rapamycin treatment (Ehninger et al., 2008).”
BackgroundSilverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438
“…and modulation of intracellular signaling mechanisms such as mTOR and PAK (Bear et al , 2004; Berry-Kravis et al , 2006; Dolen et al , 2007; Ehninger et al , 2008a; Hayashi et al , 2007; Lauterborn et al , 2000; Meikle et al , 2008; Ogier et al , 2007; Price et al , 2007; Simmons et al ,…”
The tuberous sclerosis complex
Orlova, K. A., & Crino, P. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05117.x · Cited by 401
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Krueger, D. A., Wilfong, A. A., Holland‐Bouley, K., Anderson, A. E., Agricola, K., Tudor, C., Mays, M., Lopez, C. M., Kim, M., & Franz, D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23960 · Cited by 389
“More recent studies have demonstrated that mTORC1 plays an important role in brain structure and functions not specifically tied to SEGA, SEN, or tubers,(26) with impact on neurocognition and epilepsy.(34,35) The results of our study support these earlier findings, and it is interesting to speculate whether the role o…”
ResultOsterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384
Genetic and Epigenetic Networks in Intellectual Disabilities
van Bokhoven, H. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132512 · Cited by 382
Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling
Puighermanal, E., Marsicano, G., Busquets-Garcia, A., Lutz, B., Maldonado, R., & Ozaita, A. (2009) · Nature Neuroscience · doi:10.1038/nn.2369 · Cited by 385
Exaggerated translation causes synaptic and behavioural aberrations associated with autism
Santini, E., Huynh, T. N., MacAskill, A. F., Carter, A. G., Pierre, P., Ruggero, D., Kaphzan, H., & Klann, E. (2013) · Nature · doi:10.1038/nature11782 · Cited by 368
Sala, M., Braida, D., Lentini, D., Busnelli, M., Bulgheroni, E., Capurro, V., Finardi, A., Donzelli, A., Pattini, L., Rubino, T., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.022 · Cited by 375
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370
“…(a) The persistence of late-phase LTP is increased, presumably by increasing translation of the proteins required to make synapses stronger (Ehninger et al. 2008), and (b) mGluR-LTD is inhibited by eliminating the protein synthesis required to make synapses weaker (Auerbach et al. 2011,…”
BackgroundmTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
The molecular and cellular biology of enhanced cognition
Lee, Y.-S., & Silva, A. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2572 · Cited by 361
Self-citationmTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
“Nonetheless, using a sophisticated pharmacogenetic approach to selectively inhibit mTORC1, Stoica et al. (270) provided strong direct evidence of its crucial role in both L-LTP and long-term fear memory (270).”
BackgroundInfluentialTranslational control in synaptic plasticity and cognitive dysfunction
Buffington, S. A., Huang, W., & Costa-Mattioli, M. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014100 · Cited by 348
“…A uthor M anuscript A uthor M anuscript A uthor M anuscript mice heterozygous for either Tsc1 or Tsc2 show deficits in several cognitive tasks including spatial learning in the Morris water maze, context discrimination, and fear-conditioning paradigms (Ehninger et al. 2008, Goorden et al. 2007).”
BackgroundMaking synaptic plasticity and memory last: mechanisms of translational regulation
Richter, J. D., & Klann, E. (2009) · Genes & Development · doi:10.1101/gad.1735809 · Cited by 348
“Interestingly, with more arduous training regimens, the GCN2 mutant mice have impaired LTM (Costa-Mattioli et al. 2007), which also has been observed in 4E-BP2 (Banko et al. 2005) and TSC2 (Ehninger et al. 2008) mutant mice.”
BackgroundDrug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Cognitive impairment in epilepsy: the role of network abnormalities
Holmes, G. L. (2015) · Epileptic Disorders · doi:10.1684/epd.2015.0739 · Cited by 334
Bateup, H. S., Johnson, C. A., Denefrio, C. L., Saulnier, J. L., Kornacker, K., & Sabatini, B. L. (2013) · Neuron · doi:10.1016/j.neuron.2013.03.017 · Cited by 330
“Like many other molecules genetically linked to ASDs (Bourgeron, 2009), the TSC-mTOR pathway regulates synapses such that loss-of-function mutations in Tsc1 or 2 alter excitatory synapse structure, function, and plasticity (Auerbach et al., 2011; Bateup et al., 2011; Chévere-Torres et al., 2012; Ehninger et al., 2008;…”
BackgroundResultInfluentialEffect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P. C., Howe, C. J., Doyle, T., Pointon, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 309
Betancur, C., Sakurai, T., & Buxbaum, J. D. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.04.003 · Cited by 301
“…mice (models of tuberous sclerosis), and Pten -knockout mice (which model the macrocephaly and behavioral abnormalities in ASD patients with PTEN mutations), the neurological abnormalities can be reversed by pharmacological inhibition of the mammalian target of rapamycin (mTOR) pathway [129-132] .”
BackgroundGenes, circuits, and precision therapies for autism and related neurodevelopmental disorders
Sahin, M., & Sur, M. (2015) · Science · doi:10.1126/science.aab3897 · Cited by 295
Local RNA Translation at the Synapse and in Disease: Figure 1.
Liu-Yesucevitz, L., Bassell, G. J., Gitler, A. D., Hart, A. C., Klann, E., Richter, J. D., Warren, S. T., & Wolozin, B. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4105-11.2011 · Cited by 289
“A mouse model of FXS exhibits increased mTORC1 signaling (Ehninger et al., 2008; Kelleher and Bear, 2008; Hoeffer and Klann, 2010; Sharma et al., 2010).”
BackgroundMammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
“[366], glucose intolerance via IRS-1 feedback inhibition [47] and learning impairment [330].”
BackgroundLessons learned from studying syndromic autism spectrum disorders
Sztainberg, Y., & Zoghbi, H. Y. (2016) · Nature Neuroscience · doi:10.1038/nn.4420 · Cited by 281
Synaptopathology Involved in Autism Spectrum Disorder
Guang, S., Pang, N., Deng, X., Yang, L., He, F., Wu, L., Chen, C., Yin, F., & Peng, J. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00470 · Cited by 286
“Mice with a heterozygous mutation of Tsc2 show a reduced threshold for late-phase of LTP in the CA1 region of hippocampus, which can lead to inappropriate storage of unrelated or unprocessed information, thus impairing hippocampal-dependent learning (Ehninger et al., 2008).”
BackgroundFundamental Elements in Autism: From Neurogenesis and Neurite Growth to Synaptic Plasticity
Gilbert, J., & Man, H.-Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00359 · Cited by 280
Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses
Busquets-Garcia, A., Puighermanal, E., Pastor, A., de la Torre, R., Maldonado, R., & Ozaita, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.022 · Cited by 273
Deidda, G., Parrini, M., Naskar, S., Bozarth, I. F., Contestabile, A., & Cancedda, L. (2015) · Nature Medicine · doi:10.1038/nm.3827 · Cited by 268
mTOR: A pathogenic signaling pathway in developmental brain malformations
Crino, P. B. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.008 · Cited by 266
The multiple facets of mTOR in immunity
Weichhart, T., & Säemann, M. D. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.02.002 · Cited by 259
Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259
“Using this mouse model, it was shown that brief treatment with rapamycin, an inhibitor of the mTOR complex, rescues deficits in context discrimination and spatial learning (90).”
Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations
Curatolo, P., Jóźwiak, S., & Nabbout, R. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.05.004 · Cited by 256
Magri, L., Cambiaghi, M., Cominelli, M., Alfaro-Cervello, C., Cursi, M., Pala, M., Bulfone, A., Garcìa-Verdugo, J. M., Leocani, L., Minicucci, F., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.09.008 · Cited by 256
“Recently, by targeting Tsc1 loss in differentiating/differentiated neuronal cells (Meikle et al., 2007; Ehninger et al., 2008) and astrocytes (Uhlmann et al., 2002a), several mouse models for TSC have been generated, which, although displaying epilepsy and some cortical alterations, did not fully…”
BackgroundThe Emerging Picture of Autism Spectrum Disorder: Genetics and Pathology
Chen, J. A., Peñagarikano, O., Belgard, T. G., Swarup, V., & Geschwind, D. H. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040405 · Cited by 254
Silverman, J. L., Smith, D. G., Rizzo, S. J. S., Karras, M. N., Turner, S. M., Tolu, S. S., Bryce, D. K., Smith, D. L., Fonseca, K., Ring, R. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003501 · Cited by 251
Intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms
Srivastava, A. K., & Schwartz, C. E. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.015 · Cited by 249
“Activation of the mTOR pathway increases dendritic complexity (Jaworski et al., 2005; Kumar et al., 2005) and has been observed in mouse models of Fragile X and tuberous sclerosis, two important causes of ID (Ehninger et al., 2008; Sharma et al., 2010).”
BackgroundGlutamate Synapses in Human Cognitive Disorders
Volk, L., Chiu, S.-L., Sharma, K., & Huganir, R. L. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-033821 · Cited by 248
Tsc2-Rheb signaling regulates EphA-mediated axon guidance
Nie, D., Di Nardo, A., Han, J. M., Baharanyi, H., Kramvis, I., Huynh, T., Dabora, S., Codeluppi, S., Pandolfi, P. P., Pasquale, E. B., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2477 · Cited by 248
“The hippocampal long-term potentiation (LTP) and learning abnormalities reported in Tsc-deficient mouse models could be explained, at least in part, by the involvement of the Tsc-mTOR pathway in Eph signalin”
BackgroundUzunova, G., Pallanti, S., & Hollander, E. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1085597 · Cited by 246
“…enhancing GABA functions may not be effective in TSC. Tsc2 heterozygous knockout mice show deficiency in CA1 hippocampal long-term potentiation (LTP) as result of mTOR dysregulation and learning and memory deficits that are corrected using the mTOR inhibitor rapamycin (Ehninger et al. 2008, 2009).”
BackgroundPersico, A. M., & Napolioni, V. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.06.012 · Cited by 238
The genomic landscape of tuberous sclerosis complex
Martin, K. R., Zhou, W., Bowman, M. J., Shih, J., Au, K. S., Dittenhafer-Reed, K. E., Sisson, K. A., Koeman, J., Weisenberger, D. J., Cottingham, S. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms15816 · Cited by 238
The Role of Iron in Learning and Memory
Fretham, S. J. B., Carlson, E. S., & Georgieff, M. K. (2011) · Advances in Nutrition · doi:10.3945/an.110.000190 · Cited by 235
The role of mTOR signaling in Alzheimer disease
Oddo, S. (2012) · Frontiers in Bioscience · doi:10.2741/s310 · Cited by 237
“For example, it has been shown that mTOR is hyperactive in the hippocampus of an animal model of tuberous sclerosis, a disorder associated with mental retardation, autism, and epilepsy (54).”
BackgroundInfluentialLevitt, P., & Campbell, D. B. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37934 · Cited by 234
“For example, systemic administration of drugs that reduce mTOR activation, such as rapamycin, wortmannin, and RAD001, can reverse behavioral and structural pathology in mice with Pten (43), tuberous sclerosis 1 (Tsc1) (44, 45), and neurofibromin 1 (Nf1) (46, 47) mutations, with no reported side effects.”
BackgroundStoica, L., Zhu, P. J., Huang, W., Zhou, H., Kozma, S. C., & Costa-Mattioli, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014715108 · Cited by 232
Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy
Huang, X., Zhang, H., Yang, J., Wu, J., McMahon, J., Lin, Y., Cao, Z., Gruenthal, M., & Huang, Y. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.024 · Cited by 231
Zeng, L.-H., Rensing, N. R., Zhang, B., Gutmann, D. H., Gambello, M. J., & Wong, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq491 · Cited by 233
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
The roles of protein kinases in learning and memory
Giese, K. P., & Mizuno, K. (2013) · Learning & Memory · doi:10.1101/lm.028449.112 · Cited by 233
“Brain-specific KO of FKBP12 increases mTOR activity and enhances contextual fear LTM but not STM (Hoeffer et al. 2008; but compare with Ehninger et al. 2008).”
BackgroundTranslational animal models of autism and neurodevelopmental disorders
Crawley, J. N. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.3/jcrawley · Cited by 230
Protein interactome reveals converging molecular pathways among autism disorders
Sakai, Y., Shaw, C. A., Dawson, B. C., Dugas, D. V., Al-Mohtaseb, Z., Hill, D. E., & Zoghbi, H. Y. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002166 · Cited by 226
“Benefits reported from preclinical trials using rapamycin in Pten or Tsc2mutant animals (50, 51) raise the possibility that such therapies might be beneficial in broader groups of patients with syndromic and nonsyndromic ASDs.”
BackgroundReduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model
Ricciardi, S., Boggio, E. M., Grosso, S., Lonetti, G., Forlani, G., Stefanelli, G., Calcagno, E., Morello, N., Landsberger, N., Biffo, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq563 · Cited by 223
Abnormal mTOR Activation in Autism
Winden, K. D., Ebrahimi-Fakhari, D., & Sahin, M. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061747 · Cited by 222
Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
Sato, A., Kasai, S., Kobayashi, T., Takamatsu, Y., Hino, O., Ikeda, K., & Mizuguchi, M. (2012) · Nature Communications · doi:10.1038/ncomms2295 · Cited by 220
Progress toward treatments for synaptic defects in autism
Delorme, R., Ey, E., Toro, R., Leboyer, M., Gillberg, C., & Bourgeron, T. (2013) · Nature Medicine · doi:10.1038/nm.3193 · Cited by 218
Perl, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12756 · Cited by 218
Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function
Biever, A., Valjent, E., & Puighermanal, E. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00075 · Cited by 220
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
Ehninger, D., & Silva, A. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.002 · Cited by 215
Self-citationEarly control of seizures improves long-term outcome in children with tuberous sclerosis complex
Bombardieri, R., Pinci, M., Moavero, R., Cerminara, C., & Curatolo, P. (2010) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2009.03.003 · Cited by 208
Wong, M. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02341.x · Cited by 205
“Several mouse models of TSC have been generated with abnormal neurological phenotypes, which are responsive to mTOR inhibition (Ehninger et al., 2008;Meikle et al., 2008;Zeng et al., 2008;Zhou et al., 2009).”
BackgroundLoss of Tsc1 In Vivo Impairs Hippocampal mGluR-LTD and Increases Excitatory Synaptic Function
Bateup, H. S., Takasaki, K. T., Saulnier, J. L., Denefrio, C. L., & Sabatini, B. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1617-11.2011 · Cited by 204
“The autism spectrum disorder tuberous sclerosis complex (TSC) is caused by mutations in the Tsc1 or Tsc2 genes, whose protein products form a heterodimeric complex that negatively regulates mammalian target of rapamycin-dependent protein translation.”
BackgroundInfluentialAutism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses
Won, H., Mah, W., & Kim, E. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00019 · Cited by 206
“Autism spectrum disorder (ASD) is a group of developmental disabilities characterized by abnormal social interaction and communication, and stereotyped behaviors with restricted interest.”
Backgroundde Theije, C. G. M., Wu, J., da Silva, S. L., Kamphuis, P. J., Garssen, J., Korte, S. M., & Kraneveld, A. D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.013 · Cited by 202
“Treatmentof adult Tsc2+/− mice with rapamycin reversed the learning and memory impairments (Ehninger et al., 2008).”
BackgroundDabora, S. L., Franz, D. N., Ashwal, S., Sagalowsky, A., DiMario, F. J., Miles, D., Cutler, D., Krueger, D., Uppot, R. N., Rabenou, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023379 · Cited by 204
Majumder, S., Caccamo, A., Medina, D. X., Benavides, A. D., Javors, M. A., Kraig, E., Strong, R., Richardson, A., & Oddo, S. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2011.00791.x · Cited by 203
“Toward this end, it has been shown that cognitive deficits in a mouse model of tuberous sclerosis are associated with hyperactive mTOR signaling (Ehninger et al., 2008).”
BackgroundInfluentialReversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides
Sztainberg, Y., Chen, H.-M., Swann, J. W., Hao, S., Tang, B., Wu, Z., Tang, J., Wan, Y.-W., Liu, Z., Rigo, F., et al. (2015) · Nature · doi:10.1038/nature16159 · Cited by 201
Reversing Neurodevelopmental Disorders in Adults
Ehninger, D., Li, W., Fox, K., Stryker, M. P., & Silva, A. J. (2008) · Neuron · doi:10.1016/j.neuron.2008.12.007 · Cited by 196
“…to 6-month-old mice; treatment started spatial learning deficits (Morris water maze), context discrimination, long-term potentiation phenotype Ehninger et al., 2008 neurological findings (hindlimb clasping, hypoactivity), brain enlargement and lethality Ehninger et al., 2008 neurological…”
BackgroundInfluentialSelf-citationReith, R. M., McKenna, J., Wu, H., Hashmi, S. S., Cho, S.-H., Dash, P. K., & Gambello, M. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.014 · Cited by 194
Géranton, S. M., Jiménez-Díaz, L., Torsney, C., Tochiki, K. K., Stuart, S. A., Leith, J. L., Lumb, B. M., & Hunt, S. P. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3451-09.2009 · Cited by 184
“Isolated roots were preincubated in 200 nM rapamycin (Tang et al., 2002; Ehninger et al., 2008) or vehicle (0.1% DMSO in oxygenated recovery solution) for at least 2.5 h before recording (initially at 36 37°C for 1 h then at room temperature).”
MethodInfluentialMetabolic Regulation of Neuronal Plasticity by the Energy Sensor AMPK
Potter, W. B., O'Riordan, K. J., Barnett, D., Osting, S. M. K., Wagoner, M., Burger, C., & Roopra, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008996 · Cited by 189
“upon a single high frequency stimulation in slice experiments [55].”
BackgroundPTEN signaling in autism spectrum disorders
Zhou, J., & Parada, L. F. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.05.004 · Cited by 188
Influence of seizures on early development in tuberous sclerosis complex
Capal, J. K., Bernardino-Cuesta, B., Horn, P. S., Murray, D., Byars, A. W., Bing, N. M., Kent, B., Pearson, D. A., Sahin, M., & Krueger, D. A. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.02.007 · Cited by 189
Caccamo, A., De Pinto, V., Messina, A., Branca, C., & Oddo, S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0777-14.2014 · Cited by 182
“Toward this end, mTOR activity is necessary for memory consolidation (Tang et al., 2002; Parsons et al., 2006); however, mTOR hyperactivity is detrimental and causes cognitive deficits in animals and people (Ehninger et al., 2008; Puighermanal et al., 2009; Ehninger, 2013).”
Background
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.